



ASX ANNOUNCEMENT

ANAGENICS LIMITED (ASX: AN1) – CHANGE OF DIRECTOR INTEREST NOTICES FOLLOWING COMPLETION OF ACCELERATED NON-RENONCEABLE ENTITLEMENT OFFER (ANREO)

SYDNEY, Tuesday, 14 March 2023

Anagenics Limited (**Anagenics** or the **Company**) is pleased to confirm the successful completion of the accelerated non-renounceable entitlement offer (ANREO). This saw the company raise \$3,175,702.22 (pre-costs) which will be utilised to continue funding the growth of the business.

As part of the ANREO, Anagenics provides the following Change of Director Interest Notices (Appendix 3Ys) for Dr Martin Cross and Scott Greasley following their participation in the ANREO.

Dr Martin Cross acquired 330,957 Ordinary Fully Paid Shares and Scott Greasley acquired 652,373 Ordinary Fully Paid Shares. In drafting the Appendix 3Y for Scott Greasley it was identified that the Company had inadvertently not released an Appendix 3Y following the issue of 10,000,000 performance rights to Scott Greasley on 29 December 2022. The Appendix 3Y contained within this announcement therefore includes the issue of these performance rights. The issue of these performance rights was disclosed to the ASX via the “Notification regarding unquoted securities” on 3 January 2023.

The Company, and its Directors, are aware of the obligation to disclose change of interest notices within 5 business days of the change occurring and has appropriate processes in place to comply with these requirements. In this instance the non-release of the Appendix 3Y was an administrative oversight.

Approved for release by the Company Secretary of Anagenics Limited.

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-ageing solutions. BLC Cosmetics Pty Ltd is Anagenics’ wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics’ wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see www.anagenics.com and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anagenics Limited
ABN	69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Martin Cross
Date of last notice	1 April 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	(1) NETWEALTH INVESTMENTS LIMITED (IN ITS CAPACITY AS CUSTODIAN FOR THE CROSS SUPER FUND) (2) MRS ANNA CROSS (SPOUSE)
Date of change	13 March 2023
No. of securities held prior to change	(1.1) 322,000 - ORDINARY FULLY PAID SHARES (1.2) 46,000 - OPTIONS @ \$0.18 EXP 01.04.2023 (2.1) 133,000 - ORDINARY FULLY PAID SHARES (2.2) 19,000 - OPTIONS @ \$0.18 EXP 01.04.2023
Class	ORDINARY FULLY PAID SHARES
Number acquired	(1.1) 234,215 - ORDINARY FULLY PAID SHARES (2.1) 96,742 - ORDINARY FULLY PAID SHARES
Number disposed	NIL
Value/Consideration	(1.1) \$0.022 PER ORDINARY FULLY PAID SHARES (2.1) \$0.022 PER ORDINARY FULLY PAID SHARES
No. of securities held after change	(1.1) 556,215 - ORDINARY FULLY PAID SHARES (1.2) 46,000 - OPTIONS @ \$0.18 EXP 01.04.2023 (2.1) 229,742 - ORDINARY FULLY PAID SHARES (2.2) 19,000 - OPTIONS @ \$0.18 EXP 01.04.2023

⁺ See [chapter 19](#) for defined terms.

Nature of change	Participation in the Company's Entitlement Offer as announced by the Company on 14 February 2023.
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anagenics Limited
ABN	69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Scott Greasley
Date of last notice	16 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	AG & SG Pty Ltd - Mr Greasley is a Director of this Company
Date of change	(1) 29 December 2022 (2) 13 March 2023
No. of securities held prior to change	896,882 - ORDINARY FULLY PAID SHARES
Class	(1) PERFORMANCE RIGHTS (2) ORDINARY FULLY PAID SHARES
Number acquired	(1) 10,000,000 - PERFORMANCE RIGHTS (2) 652,373 - ORDINARY FULLY PAID SHARES
Number disposed	NIL
Value/Consideration	(1) NIL (2) \$0.022 PER ORDINARY FULLY PAID SHARE
No. of securities held after change	(1) 10,000,000 - PERFORMANCE RIGHTS (2) 1,549,255 - ORDINARY FULLY PAID SHARES
Nature of change	(1) Issue of Performance Rights pursuant to Mr Greasley's Executive Services Agreement and as approved by Shareholders at the AGM held on 29 November 2022. (2) Participation in the Company's Entitlement Offer as announced by the Company on 14 February 2023.

⁺ See [chapter 19](#) for defined terms.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.